Briefing
Imlunestrant and abemaciclib for estrogen receptor-positive breast cancer with minimal residual disease (MIRI)
Phase 2 trial of abemaciclib plus imlunestrant for up to 12 cycles. The registry primary outcome is the rate of ctDNA clearance. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting